Bisphosphonate-associated osteonecrosis of the jaw

Bisphosphonate-associated osteonecrosis of the jaw (BAONJ) is a serious condition involving the loss or breakdown of the jaw bone in patients who have been treated with bisphosphonates, a class of drugs commonly used to treat osteoporosis, Paget's disease of bone, and bone cancer. This condition is also referred to as osteonecrosis of the jaw (ONJ) and has been linked to the use of both oral and intravenous forms of bisphosphonates.

Causes and Risk Factors[edit | edit source]

The exact cause of BAONJ is not fully understood, but it is believed to be related to the inhibition of bone turnover by bisphosphonates. This inhibition can lead to a decrease in the bone's ability to repair itself, making it more susceptible to necrosis. Risk factors for developing BAONJ include high doses or long-term use of bisphosphonates, invasive dental procedures (such as tooth extractions), poor oral hygiene, use of corticosteroids, smoking, and cancer treatments.

Symptoms[edit | edit source]

Symptoms of BAONJ may include pain, swelling, infection, loose teeth, and exposed bone in the mouth. These symptoms can lead to significant morbidity and a decrease in quality of life for affected individuals.

Diagnosis[edit | edit source]

Diagnosis of BAONJ is primarily based on the clinical presentation and medical history of the patient, including the use of bisphosphonates. Imaging tests, such as X-rays or CT scans, may be used to assess the extent of bone involvement. Biopsy may be performed to rule out other conditions.

Treatment[edit | edit source]

Treatment of BAONJ focuses on reducing symptoms and preventing the progression of the disease. This may include the use of antibiotics, oral rinses, and pain management strategies. In some cases, surgical intervention may be necessary to remove necrotic bone tissue. Discontinuation or modification of bisphosphonate therapy may also be considered in consultation with the patient's healthcare provider.

Prevention[edit | edit source]

Preventive measures for BAONJ include good oral hygiene, regular dental check-ups, and informing dentists about bisphosphonate therapy before undergoing any dental procedures. For patients starting bisphosphonate treatment, a dental examination and any necessary dental work are recommended prior to the initiation of therapy.

Conclusion[edit | edit source]

Bisphosphonate-associated osteonecrosis of the jaw is a complex condition that requires a multidisciplinary approach for management and treatment. Awareness and understanding of the risk factors and early signs of BAONJ are crucial for patients and healthcare providers to prevent and manage this condition effectively.